Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 3, 2011, Pages 503-509

  Al Omari, Alaa' A ^a   Al Omari, Mahmoud M ^b   Badwan, Adnan A ^b   Al Sou'od, Khaldoun A ^a  

^a AL AL BAYT UNIVERSITY   (Jordan)

^b JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY   (Jordan)

Author keywords

Candesartan cilexetil; Cyclodextrin; Molecular modelling; Solubility; Stability

Indexed keywords

BETA CYCLODEXTRIN; CANDESARTAN HEXETIL;

ANALYTIC METHOD; ARTICLE; COMPLEX FORMATION; COMPRESSION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG FORMULATION; DRUG STABILITY; ENTHALPY; ENTROPY; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MEASUREMENT; MOLECULAR MECHANICAL MODEL; ODONTOMETRY; OPTOMETRY; PHASE SOLUBILITY DIAGRAM; PRIORITY JOURNAL; SOLID STATE; THERMOGRAPHY; THERMOSTABILITY; X RAY POWDER DIFFRACTION;

ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BETA-CYCLODEXTRINS; BIPHENYL COMPOUNDS; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLODEXTRINS; DRUG STABILITY; FREEZE DRYING; HUMANS; MODELS, MOLECULAR; SOLUBILITY; SOLUTIONS; TABLETS; TETRAZOLES; THERMODYNAMICS; X-RAY DIFFRACTION;

EID: 78149499227     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.09.027     Document Type: Article

References (28)

1. Stella V.J., Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997, 14:556-567.
2. Duchene D. Cyclodextrins and Their Industrial Uses 1987, Editions de Sante', Paris (France).
3. Loftsson T., Duchene D. Cyclodextrins and their therapeutic applications. Int. J. Pharm. 2007, 329:1-11.
4. Del Valle E.M.M. Cyclodextrins and their uses: a review. Process Biochem. 2004, 39:1033-1046.
5. Ferreirós N., Dresen S., Alonso R.M., Weinmann W. Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure. J. Chromatogr. B. 2007, 855:134-138.
6. ATACAND® product monograph, (accessed 19.05.10). http://www.astrazeneca.ca/documents/ProductPortfolio/ATACAND_PM_en.pdf.
7. Cagigal E., González L., Alonso R.M., Jiménez R.M. pKa determination of angiotensin II receptor antagonistic (ARA II) by spectrofluorimetry. J. Pharm. Biomed. Anal. 2001, 26:477-486.
8. M. Tadashi, Pharmaceutical Compositions with Angiotensin-II-Antagonistic activity, Patent No. 0546358. Application No. 92119705.9, 1993.
9. Helene S., Per-Olof L., Andersen C. Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection. J. Chromatogr. B 1999, 731:411-417.
10. Subba Rao D.V., Radhakrishnanand P., Suryanarayana M.V., Himabindu V. A stability-indicating LC method for candesartan cilexetil. Chromatographia 2007, 66:499-507.
11. Mohan A., Shanmugavel S., Goyal A., Venkataraman B.R., Saravanan D. Identification, isolation, and characterization of five potential degradation impurities in candesartan cilexetil tablets. Chromatographia 2009, 69:1-10.
12. Cappello B, Di Maio C., Iervolino M., Miro A. Improvement of solubility and stability of valsartan by hydroxypropyl-β-cyclodextrin. J. Incl. Phenom. Macrocyclic Chem. 2006, 54:289-294.
13. Pravin N., Babasaheb A., Neha D., Vilasrao K., Rajashree H. Solis state characterization of the inclusion complex of valsartan with methyl β-cyclodextrin. J. Incl. Phenom. Macrocyclic Chem. 2009, 65:377-383.
14. Rajashree H., Vilasrao K. Preformulation study of the inclusion complex of irbesartan-β-cyclodextrin. AAPS PharmSciTech 2009, 10:276-281.
15. Rajashree S.H., Suneeta N.S., Vilasrao J.K. Studies on the effect of water-soluble polymers on drug-β-cyclodextrin complex solubility. AAPS PharmSciTech 2009, 10:858-863.
16. Rajesh N.K., Bhanudas S.K. Preparation, physicochemical characterization, dissolution and formulation studies of telmisartan cyclodextrin inclusion complexes. Asian J. Pharm. 2010, 4:52-59.
17. Higuchi T, Connors K.A. Phase solubility techniques. Adv. Anal. Chem. Instrum. 1965, 4:117-212.
18. 2 type phase solubility diagrams, complex formation and chemical speciation of soluble species. J. Incl. Phenom. Macrocyclic Chem. 1998, 31:243-264.
19. Zughul M.B. Rigorous nonlinear regression analysis of phase solubility diagrams to obtain complex stoichiometry and true thermodynamic drug-cyclodextrin complexation parameters. J. Incl. Phenom. Macrocyclic Chem. 2007, 57:525.
20. Ribeiro L., Veiga F. Complexation of vinpocetine with cyclodextrins in the presence or absence of polymers, binary and ternary complexes preparation and characterization. J. Incl. Phenom. Macrocyclic Chem. 2002, 44:251-256.
21. Taraszewska J., Migut K., Kozbiat M. Complexation of flutamide by native and modified cyclodextrins. J. Phys. Org. Chem. 2003, 16:121-126.
22. Yannis L.L., Varka V., Gregoriadis G. Novel non-acidic formulations of haloperidol complexed with β-cyclodextrin derivatives. J. Pharm. Biomed. Anal. 1997, 16:263-268.
23. Saichek R.E., Reddy K.R. Electrokinetically enhanced remediation of hydrophobic organic compounds in soils. Crit. Rev. Environ. Sci. Technol. 2005, 35:115-192.
24. Redenti E., Peveri T., Zanol M., Ventura P., Gnappi G., Montenero A. A study on the differentiation between amorphous piroxicam-β-cyclodextrin complex and a mixture of the two amorphous components. Int. J. Pharm. 1996, 129:289-294.
25. Matsunaga H., Eguchi T., Nishijima K., Enomoto T., Sasaoki K., Nakamura N. Solid-state characterization of candesartan cilextil (TCV-116): crystal structure and molecular mobility. Chem. Pharm. Bull. 1999, 47:182-186.
26. Cirri M., Maestrelli F., Mennini N., Mura P. Physical-chemical characterization of binary and ternary systems of ketoprofen with cyclodextrins and phospholipids. J. Pharm. Biomed. Anal. 2009, 50:683-689.
27. Allinger N.L., Yuh Y.H., Lii J.H. Molecular mechanics (MM3) force field for hydrocarbons. J. Am. Chem. Soc. 1989, 111:8551-8558.
28. Cornel W.D., Cieplak P., Bayly C.L., Gould I.R., Mertz K.M., Ferguston D.M., Spellmeyer D.C., Fox T., Caldwell J.W., Kollman P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117:5179-5197.